These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34584204)

  • 1. Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression.
    Dahlhoff J; Manz H; Steinfatt T; Delgado-Tascon J; Seebacher E; Schneider T; Wilnit A; Mokhtari Z; Tabares P; Böckle D; Rasche L; Martin Kortüm K; Lutz MB; Einsele H; Brandl A; Beilhack A
    Leukemia; 2022 Mar; 36(3):790-800. PubMed ID: 34584204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4
    Alrasheed N; Lee L; Ghorani E; Henry JY; Conde L; Chin M; Galas-Filipowicz D; Furness AJS; Chavda SJ; Richards H; De-Silva D; Cohen OC; Patel D; Brooks A; Rodriguez-Justo M; Pule M; Herrero J; Quezada SA; Yong KL
    Clin Cancer Res; 2020 Jul; 26(13):3443-3454. PubMed ID: 32220887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.
    Kawano Y; Zavidij O; Park J; Moschetta M; Kokubun K; Mouhieddine TH; Manier S; Mishima Y; Murakami N; Bustoros M; Pistofidis RS; Reidy M; Shen YJ; Rahmat M; Lukyanchykov P; Karreci ES; Tsukamoto S; Shi J; Takagi S; Huynh D; Sacco A; Tai YT; Chesi M; Bergsagel PL; Roccaro AM; Azzi J; Ghobrial IM
    J Clin Invest; 2018 Jun; 128(6):2487-2499. PubMed ID: 29558366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status.
    Foglietta M; Castella B; Mariani S; Coscia M; Godio L; Ferracini R; Ruggeri M; Muccio V; Omedé P; Palumbo A; Boccadoro M; Massaia M
    Haematologica; 2014 Oct; 99(10):1605-10. PubMed ID: 24972771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the role of Tregs in the progression of multiple myeloma.
    Lad D; Huang Q; Hoeppli R; Garcia R; Xu L; Levings M; Song K; Broady R
    Leuk Lymphoma; 2019 Sep; 60(9):2134-2142. PubMed ID: 30773086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human regulatory T cells do not suppress the antitumor immunity in the bone marrow: a role for bone marrow stromal cells in neutralizing regulatory T cells.
    Guichelaar T; Emmelot ME; Rozemuller H; Martini B; Groen RW; Storm G; Lokhorst HM; Martens AC; Mutis T
    Clin Cancer Res; 2013 Mar; 19(6):1467-75. PubMed ID: 23382115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
    Feng X; Zhang L; Acharya C; An G; Wen K; Qiu L; Munshi NC; Tai YT; Anderson KC
    Clin Cancer Res; 2017 Aug; 23(15):4290-4300. PubMed ID: 28249894
    [No Abstract]   [Full Text] [Related]  

  • 10. Treg and Oligoclonal Expansion of Terminal Effector CD8
    Joshua DE; Vuckovic S; Favaloro J; Lau KHA; Yang S; Bryant CE; Gibson J; Ho PJ
    Front Immunol; 2021; 12():620596. PubMed ID: 33708212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy.
    Sharabi A; Ghera NH
    Adv Cancer Res; 2010; 107():1-37. PubMed ID: 20399959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of regulatory T cells in multiple myeloma progression].
    Kawano Y
    Rinsho Ketsueki; 2021; 62(4):299-304. PubMed ID: 33967155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
    Xu X; Zhang C; Trotter TN; Gowda PS; Lu Y; Ponnazhagan S; Javed A; Li J; Yang Y
    Cancer Res; 2020 Mar; 80(5):1036-1048. PubMed ID: 31911552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells in vitro.
    Frassanito MA; Ruggieri S; Desantis V; Di Marzo L; Leone P; Racanelli V; Fumarulo R; Dammacco F; Vacca A
    Eur J Haematol; 2015 Jul; 95(1):65-74. PubMed ID: 25409753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.
    Ponzetta A; Benigni G; Antonangeli F; Sciumè G; Sanseviero E; Zingoni A; Ricciardi MR; Petrucci MT; Santoni A; Bernardini G
    Cancer Res; 2015 Nov; 75(22):4766-77. PubMed ID: 26438594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
    Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells.
    Braga WM; da Silva BR; de Carvalho AC; Maekawa YH; Bortoluzzo AB; Rizzatti EG; Atanackovic D; Colleoni GW
    Cancer Immunol Immunother; 2014 Nov; 63(11):1189-97. PubMed ID: 25099367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of regulatory T cells and TH17 cells in multiple myeloma.
    Braga WM; Atanackovic D; Colleoni GW
    Clin Dev Immunol; 2012; 2012():293479. PubMed ID: 22489248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.
    Guillerey C; Nakamura K; Vuckovic S; Hill GR; Smyth MJ
    Cell Mol Life Sci; 2016 Apr; 73(8):1569-89. PubMed ID: 26801219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Imbalance of treg/th17 in bone marrow of patients with multiple myeloma].
    Xing J; Lu G; Liu GQ; Xu M; Zhao X; Han F; Wang L; Ding HF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1321-5. PubMed ID: 25338581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.